Skip survey header

9937 ISTH NHF Eval

Live Meeting Evaluation

Codon optimization of transgene cDNA constructs results in: *This question is required.
In the schematic of the adeno-associated virus genome below, which element(s) is/are replaced to make an AAV therapeutic vector for gene therapy? *This question is required.
Which of the products currently in phase 3 clinical trials for hemophilia gene therapy included patients with AAV antibodies? *This question is required.
Which of the following statements best describes the efficacy of gene therapy in the clinical trials for hemophilia A utilizing the AAV5 vector? *This question is required.
DEMOGRAPHICS
1. Health Care Professional Category *This question is required.
2. Area of Primary Clinical/Laboratory Focus    *This question is required.
3. What is your role in the care of individuals with hemophilia? Select all that apply *This question is required.
6. Please rate your ability BEFORE the activity *This question is required.
Space Cell 0 - Not Relevant1 - Low2345 - High
KNOWLEDGE of gene therapy approaches in development for hemophilia A and B:
ABILITY to describe the recent clinical trial results of gene therapy for patients with hemophilia A and hemophilia B
KNOWLEDGE of the changes/modifications/additions to current hemophilia treatment protocols in order to ensure readiness for gene therapy:
7. Please rate your ability AFTER the activity *This question is required.
Space Cell 0 - Not Relevant1 - Low2345 - High
KNOWLEDGE of gene therapy approaches in development for hemophilia A and B:
ABILITY to describe the recent clinical trial results of gene therapy for patients with hemophilia A and hemophilia B:
KNOWLEDGE of the changes/modifications/additions to current hemophilia treatment protocols in order to ensure readiness for gene therapy:
PRACTICAL APPLICATION
8. Do you intend to make changes or apply new knowledge to your practice as a result of this activity? *This question is required.
If you answered yes or possibly considering changes, please check off what you intend to do differently or incorporate into your clinical management of patients as a result of this educational activity. *This question is required.
10. Was the format of this educational activity appropriate for the content presented? *This question is required.
SATISFACTION
11. Did this educational activity meet your learning needs? *This question is required.
13. Was this activity scientifically sound and free of commercial bias or influence?  *This question is required.
14. FOR EUROPEAN UNION AND UNITED KINGDOM LEARNERS ONLY:
The France Foundation would like to email you educational opportunities relevant to your practice to the address you provided. May we have your consent?